CN107298697B - Human PD-L1 protein Y123Site phosphorylation antibody and preparation method and application thereof - Google Patents
Human PD-L1 protein Y123Site phosphorylation antibody and preparation method and application thereof Download PDFInfo
- Publication number
- CN107298697B CN107298697B CN201710740882.9A CN201710740882A CN107298697B CN 107298697 B CN107298697 B CN 107298697B CN 201710740882 A CN201710740882 A CN 201710740882A CN 107298697 B CN107298697 B CN 107298697B
- Authority
- CN
- China
- Prior art keywords
- protein
- human
- antigen
- antibody
- antiserum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000026731 phosphorylation Effects 0.000 title claims abstract description 45
- 238000006366 phosphorylation reaction Methods 0.000 title claims abstract description 45
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 title claims abstract description 30
- 102000048776 human CD274 Human genes 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 34
- 239000000427 antigen Substances 0.000 claims abstract description 32
- 102000036639 antigens Human genes 0.000 claims abstract description 32
- 108091007433 antigens Proteins 0.000 claims abstract description 32
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract description 28
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 28
- 150000001413 amino acids Chemical group 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 235000018417 cysteine Nutrition 0.000 claims abstract description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims abstract description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 4
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 3
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 20
- 239000007924 injection Substances 0.000 claims description 20
- 238000003786 synthesis reaction Methods 0.000 claims description 20
- 238000002649 immunization Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 13
- 230000003053 immunization Effects 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 7
- 238000010255 intramuscular injection Methods 0.000 claims description 5
- 239000007927 intramuscular injection Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 238000010189 synthetic method Methods 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical group CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- 238000010647 peptide synthesis reaction Methods 0.000 claims 1
- 230000002787 reinforcement Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 8
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 238000004393 prognosis Methods 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 12
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000009822 protein phosphorylation Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 2
- HJDNZFIYILEIKR-OSUNSFLBSA-N Arg-Ile-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HJDNZFIYILEIKR-OSUNSFLBSA-N 0.000 description 2
- BJDHEININLSZOT-KKUMJFAQSA-N Asp-Tyr-Lys Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(O)=O BJDHEININLSZOT-KKUMJFAQSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 108010041407 alanylaspartic acid Proteins 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000010148 water-pollination Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 1
- CQJHFKKGZXKZBC-BPNCWPANSA-N Ala-Pro-Tyr Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CQJHFKKGZXKZBC-BPNCWPANSA-N 0.000 description 1
- DHONNEYAZPNGSG-UBHSHLNASA-N Ala-Val-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DHONNEYAZPNGSG-UBHSHLNASA-N 0.000 description 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 1
- VSPLYCLMFAUZRF-GUBZILKMSA-N Arg-Cys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N VSPLYCLMFAUZRF-GUBZILKMSA-N 0.000 description 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
- QQEWINYJRFBLNN-DLOVCJGASA-N Asn-Ala-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QQEWINYJRFBLNN-DLOVCJGASA-N 0.000 description 1
- XWFPGQVLOVGSLU-CIUDSAMLSA-N Asn-Gln-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N XWFPGQVLOVGSLU-CIUDSAMLSA-N 0.000 description 1
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 1
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 1
- HRGGPWBIMIQANI-GUBZILKMSA-N Asp-Gln-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HRGGPWBIMIQANI-GUBZILKMSA-N 0.000 description 1
- MYOHQBFRJQFIDZ-KKUMJFAQSA-N Asp-Leu-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYOHQBFRJQFIDZ-KKUMJFAQSA-N 0.000 description 1
- DINOVZWPTMGSRF-QXEWZRGKSA-N Asp-Pro-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O DINOVZWPTMGSRF-QXEWZRGKSA-N 0.000 description 1
- UTLCRGFJFSZWAW-OLHMAJIHSA-N Asp-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UTLCRGFJFSZWAW-OLHMAJIHSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- IXPSSIBVVKSOIE-SRVKXCTJSA-N Cys-Ser-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O IXPSSIBVVKSOIE-SRVKXCTJSA-N 0.000 description 1
- JTEGHEWKBCTIAL-IXOXFDKPSA-N Cys-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CS)N)O JTEGHEWKBCTIAL-IXOXFDKPSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- ICDIMQAMJGDHSE-GUBZILKMSA-N Gln-His-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O ICDIMQAMJGDHSE-GUBZILKMSA-N 0.000 description 1
- UTOQQOMEJDPDMX-ACZMJKKPSA-N Gln-Ser-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O UTOQQOMEJDPDMX-ACZMJKKPSA-N 0.000 description 1
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 1
- SRZLHYPAOXBBSB-HJGDQZAQSA-N Glu-Arg-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SRZLHYPAOXBBSB-HJGDQZAQSA-N 0.000 description 1
- ISXJHXGYMJKXOI-GUBZILKMSA-N Glu-Cys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O ISXJHXGYMJKXOI-GUBZILKMSA-N 0.000 description 1
- QQLBPVKLJBAXBS-FXQIFTODSA-N Glu-Glu-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QQLBPVKLJBAXBS-FXQIFTODSA-N 0.000 description 1
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 1
- WTMZXOPHTIVFCP-QEWYBTABSA-N Glu-Ile-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 WTMZXOPHTIVFCP-QEWYBTABSA-N 0.000 description 1
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 1
- UJMNFCAHLYKWOZ-DCAQKATOSA-N Glu-Lys-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O UJMNFCAHLYKWOZ-DCAQKATOSA-N 0.000 description 1
- JSIQVRIXMINMTA-ZDLURKLDSA-N Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O JSIQVRIXMINMTA-ZDLURKLDSA-N 0.000 description 1
- FGGKGJHCVMYGCD-UKJIMTQDSA-N Glu-Val-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGGKGJHCVMYGCD-UKJIMTQDSA-N 0.000 description 1
- VIIBEIQMLJEUJG-LAEOZQHASA-N Gly-Ile-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O VIIBEIQMLJEUJG-LAEOZQHASA-N 0.000 description 1
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 1
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- FIMNVXRZGUAGBI-AVGNSLFASA-N His-Glu-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FIMNVXRZGUAGBI-AVGNSLFASA-N 0.000 description 1
- YAALVYQFVJNXIV-KKUMJFAQSA-N His-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 YAALVYQFVJNXIV-KKUMJFAQSA-N 0.000 description 1
- BRQKGRLDDDQWQJ-MBLNEYKQSA-N His-Thr-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O BRQKGRLDDDQWQJ-MBLNEYKQSA-N 0.000 description 1
- NCSIQAFSIPHVAN-IUKAMOBKSA-N Ile-Asn-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NCSIQAFSIPHVAN-IUKAMOBKSA-N 0.000 description 1
- BALLIXFZYSECCF-QEWYBTABSA-N Ile-Gln-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N BALLIXFZYSECCF-QEWYBTABSA-N 0.000 description 1
- DSDPLOODKXISDT-XUXIUFHCSA-N Ile-Leu-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O DSDPLOODKXISDT-XUXIUFHCSA-N 0.000 description 1
- RENBRDSDKPSRIH-HJWJTTGWSA-N Ile-Phe-Met Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O RENBRDSDKPSRIH-HJWJTTGWSA-N 0.000 description 1
- WLRJHVNFGAOYPS-HJPIBITLSA-N Ile-Ser-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N WLRJHVNFGAOYPS-HJPIBITLSA-N 0.000 description 1
- PBCHMHROGNUXMK-DLOVCJGASA-N Leu-Ala-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 PBCHMHROGNUXMK-DLOVCJGASA-N 0.000 description 1
- MMEDVBWCMGRKKC-GARJFASQSA-N Leu-Asp-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N MMEDVBWCMGRKKC-GARJFASQSA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- LZHJZLHSRGWBBE-IHRRRGAJSA-N Leu-Lys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LZHJZLHSRGWBBE-IHRRRGAJSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- XIZQPFCRXLUNMK-BZSNNMDCSA-N Lys-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCCCN)N XIZQPFCRXLUNMK-BZSNNMDCSA-N 0.000 description 1
- MDDUIRLQCYVRDO-NHCYSSNCSA-N Lys-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN MDDUIRLQCYVRDO-NHCYSSNCSA-N 0.000 description 1
- ZEDVFJPQNNBMST-CYDGBPFRSA-N Met-Arg-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZEDVFJPQNNBMST-CYDGBPFRSA-N 0.000 description 1
- JKXVPNCSAMWUEJ-GUBZILKMSA-N Met-Met-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O JKXVPNCSAMWUEJ-GUBZILKMSA-N 0.000 description 1
- WXJLBSXNUHIGSS-OSUNSFLBSA-N Met-Thr-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WXJLBSXNUHIGSS-OSUNSFLBSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- BWTKUQPNOMMKMA-FIRPJDEBSA-N Phe-Ile-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BWTKUQPNOMMKMA-FIRPJDEBSA-N 0.000 description 1
- ZLAKUZDMKVKFAI-JYJNAYRXSA-N Phe-Pro-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O ZLAKUZDMKVKFAI-JYJNAYRXSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFGUOWQVEGTVNU-DCAQKATOSA-N Pro-Lys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OFGUOWQVEGTVNU-DCAQKATOSA-N 0.000 description 1
- GFHOSBYCLACKEK-GUBZILKMSA-N Pro-Pro-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O GFHOSBYCLACKEK-GUBZILKMSA-N 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- SFZKGGOGCNQPJY-CIUDSAMLSA-N Ser-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N SFZKGGOGCNQPJY-CIUDSAMLSA-N 0.000 description 1
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
- CRJZZXMAADSBBQ-SRVKXCTJSA-N Ser-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO CRJZZXMAADSBBQ-SRVKXCTJSA-N 0.000 description 1
- UTCFSBBXPWKLTG-XKBZYTNZSA-N Thr-Cys-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O UTCFSBBXPWKLTG-XKBZYTNZSA-N 0.000 description 1
- AYCQVUUPIJHJTA-IXOXFDKPSA-N Thr-His-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O AYCQVUUPIJHJTA-IXOXFDKPSA-N 0.000 description 1
- AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- AAZOYLQUEQRUMZ-GSSVUCPTSA-N Thr-Thr-Asn Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O AAZOYLQUEQRUMZ-GSSVUCPTSA-N 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- SJPDTIQHLBQPFO-VLCNGCBASA-N Thr-Tyr-Trp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O SJPDTIQHLBQPFO-VLCNGCBASA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- VMXLNDRJXVAJFT-JYBASQMISA-N Trp-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O VMXLNDRJXVAJFT-JYBASQMISA-N 0.000 description 1
- HKIUVWMZYFBIHG-KKUMJFAQSA-N Tyr-Arg-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O HKIUVWMZYFBIHG-KKUMJFAQSA-N 0.000 description 1
- PTFPUAXGIKTVNN-ONGXEEELSA-N Val-His-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)NCC(=O)O)N PTFPUAXGIKTVNN-ONGXEEELSA-N 0.000 description 1
- JZWZACGUZVCQPS-RNJOBUHISA-N Val-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N JZWZACGUZVCQPS-RNJOBUHISA-N 0.000 description 1
- YMTOEGGOCHVGEH-IHRRRGAJSA-N Val-Lys-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O YMTOEGGOCHVGEH-IHRRRGAJSA-N 0.000 description 1
- BGXVHVMJZCSOCA-AVGNSLFASA-N Val-Pro-Lys Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N BGXVHVMJZCSOCA-AVGNSLFASA-N 0.000 description 1
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 1
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 108010037389 glutamyl-cysteinyl-lysine Proteins 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010056787 lysyl-arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 108010082795 phenylalanyl-arginyl-arginine Proteins 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108010029384 tryptophyl-histidine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种人PD‑L1蛋白Y123位点磷酸化抗体及其制备方法和应用，属于抗体制备的生物医学技术领域，人PD‑L1蛋白Y123位点磷酸化抗体的制备方法为：半抗原合成肽通过半胱氨酸C与载体蛋白进行偶联，即得抗原；利用步骤1)抗原对动物进行免疫，并收集抗血清；将步骤2)抗血清进行纯化和选择，即为PD‑L1蛋白Y123位点磷酸化抗体；所述半抗原合成肽的氨基酸序列为CSYGGADYKRITVK，所述半抗原合成肽的酪氨酸Y位点添加有磷酸基团。本发明的人PD‑L1蛋白Y123位点磷酸化抗体能运用于恶性肿瘤诊断、治疗及预后判定中。
The invention discloses a human PD-L1 protein Y 123 phosphorylated antibody, a preparation method and application thereof, and belongs to the biomedical technical field of antibody preparation. The preparation method of the human PD-L1 protein Y 123 phosphorylated antibody is as follows: : the hapten synthetic peptide is coupled with the carrier protein through cysteine C to obtain the antigen; use the step 1) antigen to immunize the animal, and collect the antiserum; purify and select the step 2) antiserum, which is PD-L1 protein Y 123 phosphorylated antibody; the amino acid sequence of the hapten synthetic peptide is CSYGGADYKRITVK, and a phosphate group is added to the tyrosine Y site of the hapten synthetic peptide. The human PD-L1 protein Y 123 phosphorylation antibody of the present invention can be used in the diagnosis, treatment and prognosis determination of malignant tumors.
Description
Technical field
The invention belongs to the field of biomedicine technology of Antibody preparation more particularly to a kind of human PD-L 1 protein Ys123Site phosphorus
It is acidified antibody and its preparation method and application.
Background technique
According to global cancer statistics in 2016, whole world whole year, 8,200,000 patients died of cancer there are about 1.5 thousand ten thousand cancer new cases
Disease；Wherein, 57% cancer patient and 65% cancer mortality patient are from developing country.Generation, the development of tumour are
Sufficiently complex process, T cell play a crucial role in the antineoplastic immune system of body.Exempt to escape body
The monitoring of epidemic disease system, tumour cell raise apoptosis ligand 1 by various mechanism in tumor microenvironment
The expression of (programmed cell death lagand 1, PD-L1, also referred to as B7-H1), PD-L1 and T cell surface are born
Property immunologic test point-apoptosis receptor 1 (PD-1, also referred to as CD279) combine, T cell function is suppressed, Bu Nengxiang
Immune system issues the signal of attack tumour.PD-1/PD-L1 inhibitor can block the combination of PD-1 and PD-L1, block negative sense
Adjustment signal makes T cell activity recovery, to enhance immune response.
PD-L1 is selectively high to be expressed in tumor tissues.PD-L1 is the transmembrane glycopeptide being made of 290 amino acid
It is white, belong to B7-CD28 superfamily member, amino acid sequence is as shown in SEQ ID NO:1.Studies have shown that PD-L1 at present
MRNA is transcribed extensively in Normal Human Tissue and organ, wherein high transcription, spleen, lymph in placenta, heart, lungs and liver
It ties, low transcription in thymus gland, is not transcribed in central nervous system.However, corresponding PD-L1 albumen is not translated extensively in normal but
In tissue, only a small amount of translation is in tonsillotome, lungs, the macrophage of liver and immune special permission region, PD-L1 albumen
It is translated in eyes and placenta.Translation of the PD-L1 in the transcription and epicyte protein level in mRNA level in-site has differences, this
Imply a kind of expression of important mechanism regulating PD-L1 albumen.In recent years, hand is detected by immunohistochemical method (IHC)
Art or biopsy specimen, discovery PD-L1 albumen are a variety of swollen in melanoma, breast cancer, non-small cell lung cancer (NSCLC), kidney etc.
High expression in tumor, and low expression or do not express in the normal tissue.PD-L1 albumen low expression in normal tissue and inductivity
It is that it is different from other most significant features of co-suppression signal path that height, which is expressed in tumor tissues, which imply that PD-L1 albumen
Selectively it is expressed in tumor tissues, it is closely related with tumor microenvironment.These are found to be immunotherapy of tumors and provide
Important target spot, to obtain better curative effect and lower toxic side effect.
With the proposition of accurate medical concept, the research in relation to immunization therapy is got growing concern for.PD-1/ PD-
L1 immunotherapy is a kind of anticancer immunotherapy currently to attract attention, it is intended to be resisted using the immune system of human body itself swollen
Tumor: it is suitable for multiple types tumour by blocking PD-1/PD-L1 signal path to make death of neoplastic cells.Each research institution by
Step carries out corresponding Clinical Project, the effect of single medication and conjoint therapy treating cancer is investigated, to excavate such drug
Clinical value.Currently, opdivo has been suitable for melanoma in Japan, it is suitable for melanoma and non-small cell lung in the U.S.
Cancer, in the granted melanoma idicatio of European Union, while opdivo has obtained the support of European Union CHMP for the application of lung cancer therapy.
MSD Corp. keytruda is expected in the recent period in the U.S.'s granted melanoma idicatio through non-small cell lung cancer adaptation
Card approval, while keytruda has obtained European Union CHMP support for the application of melanoma treatment.However, Astrazeneca AB
MEDI4736 and the RG7446 of Roche Holding Ag not yet harvest any idicatio at present.The well-known medical market survey institute in the whole world
Evaluatepharma prediction: opdivo will become one of most successful immunotherapeutic agents preparation.
Compare concentration for the research of PD-1/PD-L1 at present, but is the absence of the exploitation of novel targets, " immunization therapy " treatment
Mode standardizes not enough.Although PD-1 inhibitor and targeting medicine (being directed to cancer cell) have basic difference, resistance problems
It still remains, it is necessary to further research and develop novel targets.
It is existing the study found that the occurrence and development of tumour to be frequently accompanied by the modification of PD-L1 protein phosphorylation abnormal. PD-L1
Sulphation modification plays key effect in the physiology and pathologic process that PD-1/PD-L1 signal path mediates after protein translation,
The phosphorylation level of PD-L1 albumen has very important significance for the control accurate of PD-1/PD-L1 signal path.
Therefore, it is necessary to develop a kind of human PD-L 1 protein phosphorylation antibody, which is applied to malignant tumour
During diagnosis, treatment and prognosis determine, while developing the novel targets of cancer.
Summary of the invention
Present invention aims to overcome that the shortcomings of the prior art, and a kind of human PD-L 1 albumen for cancer is provided
Y123Site phosphorylation antibody and its preparation method and application.To achieve the above object, the technical scheme adopted by the invention is as follows: one
Kind human PD-L 1 protein Y123The hapten synthesis peptide of site phosphorylation antibody, the amino acid sequence of the hapten synthesis peptide is such as
Shown in SEQ ID NO:2, the tyrosine Y-site of the hapten synthesis peptide is added with phosphate group.
As an improvement of the above technical solution, the N-terminal of the hapten synthesis peptide is connected with a cysteine C.
In addition, the present invention also provides the synthetic methods of the hapten synthesis peptide, successively the following steps are included: using polypeptide
The amino acid sequence of synthetic technology synthesis polypeptide, the polypeptide is SYGGADYKRITVK, and the tyrosine Y-site of the polypeptide adds
Add phosphate group, the N-terminal of the polypeptide connects a cysteine C.The hapten synthesis peptide are as follows: (NH2-) CSYGGAD
(pY)KRITVK(-COOH)。
In addition, the present invention also provides a kind of human PD-L 1 protein Ys123The preparation method of site phosphorylation antibody, including it is following
Step:
1) hapten synthesis peptide described in claim 1 is passed through into cysteine C and carrier protein (carrier hemocyanin
KLH or bovine serum albumin BSA) it is coupled to get antigen；
2) animal is immunized using antigen described in step 1), and collects antiserum；
3) the step 2) antiserum is purified and is selected, as PD-L1 protein Y123Site phosphorylation antibody.
As an improvement of the above technical solution, the step 2) immunization ways specifically: 1 initiation injection, 3~4 times plus
Injection is penetrated and 1 direct injection；The initiation injection and booster shots are equal are as follows: move antigen synthetic peptide and adjuvant combined immunization
Object, in the relatively thin and loose position two sides subcutaneous injection of neck, skin of back, intramuscular injection is distinguished in gluteus and huckle two sides,
The intracutaneous injection of waist two sides, footpad injection；The direct injection are as follows: antigenic solution intramuscular injection.
As an improvement of the above technical solution, it in the step 3), is purified by following steps implementation: measuring before purification
Antiserum is directed to the potency of antigen, determines that antiserum before purification can identify antigen；The antiserum of collection is purified, is determined
Antiserum energy specific recognition phosphorylated human PD-L1 albumen after purification.
Preferably, whether the antiserum of collection is tested measurement antiserum for the potency of antigen with Elisa and its can be known
Other antigen；It is purified using affine separation-affinity purification circulating technology antagonistic Serum, with Dot blot and Western
Blot test determines whether antiserum after purification being capable of specific recognition phosphorylated human PD-L1 albumen.
In addition, the present invention also provides the human PD-L 1 protein Ys that the preparation method is prepared123Site phosphorylation antibody.
In addition, the pharmaceutical preparation includes the human PD-L 1 protein Y the present invention also provides a kind of pharmaceutical preparation123Site
Phospho-AB.
In addition, the present invention also provides the human PD-L 1 protein Ys123Site phosphorylation antibody is examined in preparation for malignant tumour
The application for the pharmaceutical preparation that disconnected, treatment and prognosis determine.
In addition, the present invention also provides the applications that the pharmaceutical preparation determines in diagnosis of malignant tumor, treatment and prognosis.
The beneficial effects of the present invention are: the present invention provides a kind of human PD-L 1 protein Y123Site phosphorylation antibody and its system
Preparation Method and application list PD-L1 protein Y in technical solution of the present invention123Site phosphorylation antibody, its hapten synthesis peptide
And the preparation method of the two, human PD-L 1 protein Y123Site phosphorylation antibody can detect that human PD-L 1 protein phosphorylation is horizontal
With suspension PD-1/PD-L1 cell-signaling pathways, facilitate to study PD-L1 protein phosphorylation in this way in PD-1/PD-L1 cell letter
The effect of number access and occurrence mechanism on cancer provide for the diagnosis or treatment of clinical tumor disease and search out potential effect target
Point；It simultaneously can also be by human PD-L 1 protein Y123Site phosphorylation antibody applies to diagnosis of malignant tumor, treatment and prognosis and determines
In.
Detailed description of the invention
Fig. 1 is the antigen protein electrophoretogram in the embodiment of the present invention 3；
Fig. 2 is to scheme in the embodiment of the present invention 3 by the antigen Western blot of primary antibody of negative serum；
Fig. 3 is antiserum titre Elisa analysis chart in the embodiment of the present invention 3；
Fig. 4 is to close Western blot figure by the antigen of primary antibody of antiserum before purification in the embodiment of the present invention 4；
Fig. 5 is to close Western blot figure by the antigen of primary antibody of antiserum after purification in the embodiment of the present invention 4；
Fig. 6 is the immunohistochemistry figure of phosphorylation PDL-1 albumen in people's lung squamous cell carcinoma cancers in the embodiment of the present invention 4；
Fig. 7 is the phosphorylation PDL-1 of people's normal esophageal scaly epithelium and esophageal squamous cell carcinoma in the embodiment of the present invention 4
Immunoreaction scorings chemical staining figure.
Specific embodiment
Purposes, technical schemes and advantages in order to better illustrate the present invention, below in conjunction with specific embodiment, subordinate list and attached
The invention will be further described for figure.
Embodiment 1 determines human PD-L 1 protein phosphorylation site
Being screened first by bioinformatics software NetPhorest 2.0 and NetPhos 2.0 may in human PD-L 1 albumen
The site of phosphorylation occurs, then looking by mass spectrum document and protein phosphorylation site database PhosohoSitePlus
It looks for, determines Y123Site is a phosphorylation site in human PD-L 1 amino acid sequence；Software CLC Protein is utilized simultaneously
Workbench 5 calculates the antigenicity and hydrophily of human PD-L 1 amino acid sequence, final to determine human PD-L 1 protein-specific phosphorus
Polyadenylation sites are 123 amino acid-tyrosine Y123。
There are multiple phosphorylation site (such as Y for human PD-L 1 albumen28Site), since subsequent antigenicity and hydrophily are discontented
Sufficient test requirements document, is not suitable as phosphorylation site.
Embodiment 2 synthesizes hapten synthesis peptide
According to the design of hapten synthesis peptide, in Y123A phosphate group is added on site, carries out HPLC (efficient liquid
Phase chromatography) separation, purifying, the purity for obtaining hapten synthesis peptide is 95% or more.Correspondingly, one section of Y is synthesized123Site
The synthetic peptide of non-phosphorylating, and the affine filler for separating chromatography, warp are used as with bovine serum albumin coupling by the cysteine of N-terminal
Purity after HPLC is isolated and purified is 90% or more.
Embodiment 3 prepares antiserum
3.1 prepare negative serum
Take 3mL blood in heparin tube from the ear vein of the new zealand white rabbit (2~3kg, female are healthy and strong) for injection
In, with cotton balls hemostasis by compression.Blood is set into room temperature 1h or so, waits for blood to solidify to form clot, 2h is placed at 4 DEG C analyses serum
Out, 2500g be centrifuged 10min, draw supernatant, be labeled as negative control sera, dispense and be stored in -20 DEG C it is to be measured.
3.2 immune preceding screening-Western blot (protein blot):
BCA (Bicinchoninic acid) protein concentration detection kit measures solubilized phosphoantigen (pY123-
BSA antigen (the Y of concentration and non-phosphorylating)123- BSA) concentration, respectively 0.845mg/mL and 1.1mg/mL (phase relation
Number R=0.991).By pY123- BSA and Y123- BSA carries out protein electrophoresis, and as a result swimming lane 1 is Y as shown in Figure 1:123- BSA, swimming lane
2 be pY123-BSA.Due to synthetic peptide be it is artificial synthesized, protein band is one section of thick wide band；Because phosphorylation modification makes
pY123The molecular weight of-BSA is larger and band is slightly above Y123The band of-BSA.
Take dissolved purifying antigen (pY123-BSA、Y123- BSA) 5 μ g, 5 × SDS sample-loading buffer appropriate, boiling is added
10min is boiled in water-bath makes protein denaturation, and 10000 × g is centrifuged 10min；The volumetric concentration of SDS-PAGE electrophoretic separation glue is
10%, the volumetric concentration that glue is concentrated is 5%.Sample loading gun loading is used in order, in unused sample well plus isometric 5 ×
Sds gel sample-loading buffer；It is changed to 100V 70min after 60V 20min electrophoresis, until bromophenol blue reaches the bottom of separation gel, is closed
Close power supply.Transferring film condition: constant current 180 mA, time 180min.The closing of 5% skimmed milk power, 37 DEG C of 2h of shaking table.Transfer film is put
Enter and prepare immune preceding antiserum dilution by 1:5000 with TBST buffer, level slowly shakes up, and 4 DEG C overnight.37 DEG C of next day works
With 20min, primary antibody solution is abandoned, 1 × TBST washes film 10min, is repeated 4 times.Film is placed in diluted by 1:5000 with 1 × TBST
In the secondary antibody diluent of the goat anti-rabbit igg of HRP label, 37 DEG C of shaking table, 50min.Two corresponding anti-solution is abandoned, 1 × TBST washes film 10min,
It is repeated 3 times.Developed according to producer's explanation using ECL kit, is photographed to record.As a result as shown in Fig. 2, not occurring purpose band,
Do not occur the antibody for purpose tissue or cell extract, is gedanken experiment animal；Wherein swimming lane 1,2,3 is respectively Y123-
BSA、pY123-BSA、 BSA。
3.3 animal immunes (duration is about 73d)
3.31 draw antigenic solution, another syringe draws equal amounts Freund's complete adjuvant with an asepsis injector
(CFA), it is connected with plastic tube therebetween, is aspirated back and forth, until forming the emulsion emulsified completely, drop Yu Shuizhong does not expand
It dissipates.
3.32 first immunisations are respectively through neck, position two sides subcutaneous (s.c) injection that skin of back is relatively thin, loose, gluteus
With huckle two sides difference muscle (i.m) injection, waist two sides carry out intradermal (i.d) injection, and rabbit palmula position injection etc. is more
Position multi-point injection antigen emulsion.About 0.61 mg of antigen total amount of first immunisation.
After 3.33 first immunisation 20d carry out first time booster immunization, use incomplete Freund's adjuvant (IFA) replace CFA as
Immunologic adjuvant prepares antigen emulsion and is injected by first immunisation mode, and this time the antigen total amount of booster immunization is each about
0.9mg。
It is carried out after 3.34 immune 12d plus second strong immune, uses IFA to replace CFA as immunologic adjuvant and prepare antigen emulsus
Liquid is simultaneously injected by first immunisation mode, and this time the antigen total amount of booster immunization is each about 0.9mg.
After 3.35 immune 10d, from ear vein blood sampling 5mL, blood is set into room temperature 1h or so, waits for blood to solidify to form clot, 4
2h is placed at DEG C is precipitated serum, and 3500g is centrifuged 10min, draws supernatant, is labeled as positive antiserum, dispenses and be stored in -20
It is DEG C to be measured.
1:1000,1:5000,1:10000 dilute 3.36 positive antiserums in proportion, carry out Elisa and detect antibody titer,
OD value to be measured is 1.0 or more, and the P/N value difference 7.0,7.4 and 7.3 of the positive antiserum of each dilution, then serum is anti-at this time
Body potency is at least 1:5000.Antibody titer reaches expected horizontal (the potency > 1:1000 of Elisa), carries out most before a large amount of blood samplings
A booster immunization afterwards: antigenic solution (pY123- KLH) direct intramuscular injection rabbit, about 0.6mg.
After 3.37 last time booster immunization 3d, rabbit carries out the big blood sampling of abdominal aorta, largely collects antiserum.It will collect
Room temperature is stood overnight after having the beaker of blood to close, and makes clot contraction.The serum of precipitation is sub-packed in 50mL by next day sterile working
In centrifuge tube, 4000g is centrifuged 10min, takes supernatant, and every pipe dispenses 1mL, labeled as immune rear antiserum (about 51mL altogether), storage
In -20 DEG C.
3.38 immune rear sero-fast titrations: antigen is diluted with antigen coat liquid, makes 2 μ g/mL of its concentration, presses
(serum origin and the new zealand white rabbit being immunized, number of animals is respectively RB7771 to concentration gradient dilution antiserum in table 1
And RB7772), and illustrate to be operated according to Elisa kit, testing result is as shown in table 1 and Fig. 3.In table 1 and Fig. 3
In, SA indicates the antibody after Streptavidin-biotin-antigen system affinity purification；(-) indicates affine pure without the system
The antibody of change, i.e. negative control；Blank is blank control；P-Ab refers to that hapten synthesis peptide phosphorylation, NP-Ab are in antigen
The non-phosphorylation of hapten synthesis peptide in antigen.
Table 1 is immune rear sero-fast titration result
4 specificity identification human PD-L 1 protein Y of embodiment123Site phosphorylation antibody
The specificity of 4.1Western blot detection purified antibodies:
BCA protein concentration detection kit measures solubilized pY123- BSA and Y123The concentration of-BSA, concentration are respectively
0.692mg/mL and 0.647mg/mL (coefficient R=0.9952).Dissolved 5 μ g of purifying antigen is respectively taken, is added appropriate 5
× SDS sample-loading buffer, boiling water bath, which boils 10min, makes protein denaturation, and 10000 × g is centrifuged 10min.On Western blot
Sample analysis, wherein primary antibody solution is the purified antibodies dilution of 1:500 and the antiserum dilution before purification of 1:10000.Knot
Fruit is as shown in Figure 4 and Figure 5, and the primary antibody of Fig. 4 is antiserum dilution before purification, and BSA swimming lane is without there is specific band, Y123-
The swimming lane and pY of BSA123The swimming lane of-BSA has specific band；The primary antibody of Fig. 5 is antiserum dilution after purification, BSA
Swimming lane and Y123The swimming lane of-BSA is without there is specific band, pY123The swimming lane of-BSA has specific band.Therefore, after purification
The hapten synthesis peptide-BSA of antibody energy specific recognition phosphorylation (i.e. the antigen of phosphorylation can also identify people's phosphorylation PD-
L1 albumen).
4.2 immune group chemical identification antibody specificities
User's lung phosphorus cancerous tissue first after specimens paraffin embedding slices, is microscopy after immunohistochemical staining, result such as Fig. 6
Shown, phosphorylation PDL-1 albumen navigates to cell membrane, navigates to cytoplasm on a small quantity, can be used as positive control.Then respectively with just
Often tissue and cancer of the esophagus tumor tissues do paraffin section, and the microscopy after immune group chemical staining, result is as shown in fig. 7,400x
Epithelial cell is coloured without specificity in visible normal esophageal squamous epithelial tissue under times, and tumour cell is special in esophageal squamous cell carcinoma tissue
Opposite sex coloring positive rate accounts for about 40%., phosphorylation PDL-1 albumen is primarily targeted for cell membrane, navigates to cytoplasm on a small quantity.With sun
Property results of comparison is consistent.Illustrate the expression of phosphorylation PDL-1 albumen in the detectable human esophageal carcinoma of the present invention.
The preservation of 4.3 antibody
Final concentration of 2.5%BSA (wt/vol), 0.01%Tween-20 (vol/ is added in IgG positive combined hybrid liquid
Vol) and the mixed liquor of 25% glycerol (vol/vol), every pipe are packed as 1mL, -80 DEG C of long-term preservations.
5 human PD-L 1 protein Y of embodiment123Application of the site phosphorylation antibody in tumour
The human PD-L 1 protein Y of high specific is prepared in 5.1 present invention123Site phosphorylation antibody can use Western
The differential expression of tumour cell after the detectable normal cell of blot experiment, tumour cell and medication.
5.2 antibody provided by the invention can be applied to detect in the immunological testings such as ICC, Elisa in practical applications
Phosphorylation modification situation after the transcription of human PD-L 1 albumen, to inquire into the modification of human PD-L 1 protein phosphorylation in tumor-related illness
In meaning.
The activation of 5.3 human PD-L 1 albumen depends on phosphorylation modification, prevents its phosphorylation that from can preventing withering for lymphocyte
It dies, therefore antibody is convenient for studying human PD-L 1 protein Y in practical applications123Site phosphorylation is modified for particular biological event
Such as immunoregulatory influence, to inquire into its effect during the disease developments such as tumour.
5.4 antibody provided by the invention help to inquire into the phosphorylation modification of PD-L1 albumen in tumor disease occurrence and development
Mechanism of action in the process is more conducive to the research for inhibiting drug to tumor inhibition effect in clinical application.
5.5 the present invention be directed to the specific Y of human PD-L 1 albumen123The phosphorylation polyclonal antibody of site preparation, helps to grind
Study carefully the zymogenesis for mediating it that phosphorylation occurs, inquire into human PD-L 1 albumen multiple biological function in T cell-signaling pathways and
Albumen/nucleic acid interaction network, to find the latent effect target spot of the diagnosing and treating of clinical tumor disease.
Finally, it should be noted that above embodiments protect the present invention to illustrate technical solution of the present invention
The limitation of range, although the invention is described in detail with reference to the preferred embodiments, those skilled in the art should be managed
Solution, can modify to technical solution of the present invention or replace on an equal basis, without departing from technical solution of the present invention essence and
Range.
Sequence table
<110>Zhang Hao
<120>a kind of 123 site phosphorylation antibody of human PD-L 1 protein Y and its preparation method and application
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 290
<212> PRT
<213> Homo sapiens
<400> 1
Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu
1 5 10 15
Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr
20 25 30
Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu
35 40 45
Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile
50 55 60
Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser
65 70 75 80
Tyr Arg Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn
85 90 95
Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr
100 105 110
Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val
115 120 125
Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val
130 135 140
Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr
145 150 155 160
Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser
165 170 175
Gly Lys Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn
180 185 190
Val Thr Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr
195 200 205
Cys Thr Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu
210 215 220
Val Ile Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His
225 230 235 240
Leu Val Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr
245 250 255
Phe Ile Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys
260 265 270
Gly Ile Gln Asp Thr Asn Ser Lys Lys Gln Ser Asp Thr His Leu Glu
275 280 285
Glu Thr
290
<210> 2
<211> 14
<212> PRT
<213>artificial sequence
<400> 2
Cys Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val Lys
1 5 10
Claims (5)
1. a kind of human PD-L 1 protein Y123The hapten synthesis peptide of site phosphorylation antibody, it is characterised in that: the haptens closes
At the amino acid sequence of peptide as shown in SEQ ID NO:2, the hapten synthesis peptide is added with close to the tyrosine Y-site of C-terminal
Phosphate group.
2. the synthetic method of hapten synthesis peptide as described in claim 1, it is characterised in that: successively the following steps are included: using
Peptide synthesis technology synthesis polypeptide, the amino acid sequence of the polypeptide are SYGGADYKRITVK, junket of the polypeptide close to C-terminal
Propylhomoserin Y-site adds phosphate group, and the N-terminal of the polypeptide connects a cysteine C.
3. a kind of human PD-L 1 protein Y123The preparation method of site phosphorylation antibody, it is characterised in that: the following steps are included:
1) hapten synthesis peptide described in claim 1 is coupled by cysteine C and carrier protein to get antigen；
2) animal is immunized using antigen described in step 1), and collects antiserum；
3) the step 2) antiserum is purified and is selected, as PD-L1 protein Y123Site phosphorylation antibody.
4. human PD-L 1 protein Y as claimed in claim 3123The preparation method of site phosphorylation antibody, it is characterised in that: the step
Rapid 2) immunization ways specifically: 1 initiation injection, 3~4 booster shots and 1 direct injection；The initiation injection and reinforcement
Injection is equal are as follows: by antigen synthetic peptide and adjuvant combined immunization animal, is subcutaneously injected in neck, back two sides, gluteus and huckle
Distinguish intramuscular injection, the intracutaneous injection of waist two sides, footpad injection in two sides；The direct injection are as follows: antigenic solution intramuscular injection.
5. human PD-L 1 protein Y as claimed in claim 3123The preparation method of site phosphorylation antibody, it is characterised in that: the step
It is rapid 3) in, be purified by following steps implementation: measuring the potency that antiserum before purification is directed to antigen, determine anti-blood before purification
Antigen can be identified clearly；The antiserum of collection is purified, determines antiserum energy specific recognition phosphorylated human PD- after purification
L1 albumen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710740882.9A CN107298697B (en) | 2017-08-24 | 2017-08-24 | Human PD-L1 protein Y123Site phosphorylation antibody and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710740882.9A CN107298697B (en) | 2017-08-24 | 2017-08-24 | Human PD-L1 protein Y123Site phosphorylation antibody and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107298697A CN107298697A (en) | 2017-10-27 |
| CN107298697B true CN107298697B (en) | 2019-05-24 |
Family
ID=60132520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710740882.9A Active CN107298697B (en) | 2017-08-24 | 2017-08-24 | Human PD-L1 protein Y123Site phosphorylation antibody and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107298697B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109694412A (en) * | 2018-12-12 | 2019-04-30 | 深圳市雅臣智能生物工程有限公司 | Block the IgY and small molecule Fab antibody, preparation and application of PD-1/PD-L1 access |
| CN111363031B (en) * | 2020-03-03 | 2022-03-11 | 中国人民解放军军事科学院军事医学研究院 | pSer131 polyclonal antibody of BNIP3 and its preparation method and application |
| CN112480249B (en) * | 2020-11-26 | 2022-09-13 | 北京大学第三医院（北京大学第三临床医学院） | Preparation method and application of phosphorylated antibody product of AKT (alkyl ketene dimer) new substrate HIP-55 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105585636B (en) * | 2015-11-24 | 2020-03-03 | 南方医科大学 | Human NOTCH1NICD protein Ser2162 site phosphorylation antibody and preparation method and application thereof |
| CN106939047B (en) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | PD-L1 antibody and preparation method thereof |
-
2017
- 2017-08-24 CN CN201710740882.9A patent/CN107298697B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107298697A (en) | 2017-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2753360T3 (en) | Antibodies to PD-L1 and uses thereof | |
| CA2427643C (en) | Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) | |
| CN107298697B (en) | Human PD-L1 protein Y123Site phosphorylation antibody and preparation method and application thereof | |
| CN108752454B (en) | A kind of human CYR61 protein Ser188 phosphorylated antigen, antibody and preparation method and application thereof | |
| CN108840920B (en) | Human CYR61 protein Ser167 site phosphorylation antigen and antibody, and preparation method and application thereof | |
| CN103923212A (en) | EHD2 antibody and application of EHD2 antibody to preparation of immunohistochemical detection reagent for breast cancer | |
| CN101189266A (en) | Cytotoxicity mediation of cells evidencing surface expression of CD63 | |
| CN101897961B (en) | Preparation method for B cell CD 22 extracellular inhibitive peptide fragment B2285 vaccines | |
| CN105017403B (en) | The preparation and its application of cancer of pancreas related polypeptide DAP44 monoclonal antibodies | |
| CN107522785B (en) | anti-EGFR mutant III monoclonal antibody, preparation method and application thereof | |
| CN104402985B (en) | The antigen protein and its rabbit polyclonal antibody and purposes of anti-scaffold molecule 1-s antibody | |
| CN111363031B (en) | pSer131 polyclonal antibody of BNIP3 and its preparation method and application | |
| Zhang et al. | Monoclonal antibody recognizing a carcinoembryonic antigen epitope differentially expressed in human colonic carcinoma versus normal adult colon tissues | |
| CN103788210A (en) | Specific antibody of phosphorylated aromatase | |
| CN101962405A (en) | Humanized breast cancer antigen and antibody thereof | |
| CN104945496B (en) | A kind of polypeptide and its application in the preparation and purification antibody special to EHD2 | |
| CN109593131B (en) | Monoclonal antibody for resisting 14-3-3 eta protein and application thereof | |
| CN101671394B (en) | Antibody of anti hAPE1 protein and preparation method thereof as well as kit applying antibody | |
| JPH11508235A (en) | Tumor-associated epitope | |
| CN105693863B (en) | Anti-fusion protein CEA576-669HSP70L1 monoclonal antibody 3C1 and use thereof | |
| CN109134656A (en) | A kind of anti-HER2 polyclonal antibody | |
| Gold | Tumor-specific antigen in GI cancer | |
| CN107589262B (en) | For detecting the kit of breast cancer | |
| CN100396698C (en) | A new breast cancer related protein and its specific polyclonal antibody | |
| CN100567323C (en) | Preparation and application of testis-specific protein 50 monoclonal antibody and polyclonal antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200305 Address after: 515000 No. 22 Ling Road, Guangdong, Shantou Patentee after: SHANTOU UNIVERSITY MEDICAL College Address before: 515000 Medical School of Shantou University, 22 Xin Ling Road, Jinping District, Guangdong, Shantou Patentee before: Zhang Hao |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220509 Address after: 510660 No. 6, Huangcun North Road, Tianhe District, Guangzhou, Guangdong Patentee after: Guangzhou Huake Biotechnology Co.,Ltd. Address before: No.22, Xinling Road, Shantou, Guangdong 515000 Patentee before: SHANTOU UNIVERSITY MEDICAL College |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20241028 Address after: 510632 No. 601, Whampoa Avenue, Tianhe District, Guangdong, Guangzhou Patentee after: Zhang Hao Country or region after: China Address before: 510660 No. 6, Huangcun North Road, Tianhe District, Guangzhou, Guangdong Patentee before: Guangzhou Huake Biotechnology Co.,Ltd. Country or region before: China |